Results 71 to 80 of about 11,301 (165)

Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting

open access: yesClinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lactate accumulation links metabolic reprogramming to epigenetic regulation via protein lactylation. Lactylation drives colorectal cancer proliferation, metastasis, immune escape and chemoresistance. Microbiota‐derived lactate shapes a tumour‐specific lactylation landscape in colorectal cancer.
Ming Liu   +6 more
wiley   +1 more source

Bioactive Phenolic Compounds in Extra Virgin Olive Oil: Implications for Cardiovascular Health

open access: yesFood Science &Nutrition, Volume 14, Issue 2, February 2026.
Extra virgin olive oil (EVOO) is rich in bioactive polyphenols that exert antioxidant, anti‐inflammatory, and anti‐atherogenic effects. These compounds improve endothelial function, modulate lipid metabolism, and reduce platelet aggregation, contributing to cardiovascular protection. Regular consumption of phenolic‐rich EVOO, as part of a Mediterranean
Cristina Vázquez‐Jiménez   +5 more
wiley   +1 more source

Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study

open access: yesHealth Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Apolipoprotein E (APOE) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are both lipid proteins and related to immunity/inflammation. We hypothesized that PCSK9 impacts on Alzheimer's disease (AD) risk in an APOE genotype dependent manner.
Qiushan Tao   +10 more
wiley   +1 more source

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

open access: yesDiseases
The primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease.
José Seijas-Amigo   +20 more
doaj   +1 more source

PCSK9 inhibitors [PDF]

open access: yesNursing Critical Care, 2019
PCSK9 inhibitors.
openaire   +2 more sources

Progress in RNA‐Targeted Therapeutics for Human Diseases

open access: yesMedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang   +10 more
wiley   +1 more source

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk

open access: yesQuality in Sport
Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety.
Radosław Szydłowski   +7 more
doaj   +1 more source

Metabolic Dysfunction and Coronary Plaque Vulnerability: The Predictive Role of Insulin Resistance Indices in Cardiovascular Outcomes

open access: yesMedComm, Volume 7, Issue 2, February 2026.
ABSTRACT Significant residual cardiovascular risk persists in patients diagnosed with coronary artery disease despite intensive lipid‐lowering therapy. Although insulin resistance (IR) is an established epidemiological risk factor, the biological mechanisms by which it promotes plaque destabilization remain poorly understood.
Yue Yu   +11 more
wiley   +1 more source

Beyond lipids: Systemic effects of lipoprotein apheresis

open access: yes
Transfusion, EarlyView.
Menatalla Nadim, Yamac Akgun
wiley   +1 more source

Rethinking Statin Dosage in Coronary Disease

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
It is widely acknowledged that a sufficient statin dose is important in the management of symptomatic coronary disease, along with weight reduction and appropriate antithrombotic, blood pressure, and diabetes pharmacotherapy. Mid‐range statin doses have been shown to achieve the maximum improvements in total mortality and have the advantage of greater ...
Simon B. Dimmitt   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy